Lymphoproliferative response to HIV type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDS-free infection

AIDS Research and Human Retroviruses

Volumn 15, Issue 11, 1999, Pages 973-981

  Pontesilli, Oscar ^a,c   Carotenuto, Patrizia ^a   Kerkhof Garde, Susana R ^a   Roos, Marijke T M ^a   Keet, Ireneus P M ^b   Coutinho, Roel A ^b   Goudsmit, Jaap ^a   Miedema, Frank ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MUNICIPAL HEALTH SERVICE   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INFECTION; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

ADULT; CD4 LYMPHOCYTE COUNT; CELL DIVISION; CELLS, CULTURED; COHORT STUDIES; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HOMOSEXUALITY, MALE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; RNA, VIRAL; SURVIVORS;

EID: 0033587657     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310485     Document Type: Article

References (45)

1. Lifson AR, Rutheford GW, and Jaffe HW: The natural history of human immunodeficiency virus infection. J Infect Dis 1988;158: 1360-1367.
2. Klein MR and Miedema F: Long-term survivors of HIV-1 infection. Trends Microbiol 1995;3:386-391.
3. Klein MR, van Baalen CA, Holwerda AM, Kerkhof-Garde SR, Bende RJ, Keet IPM, Eeftink-Schattenkerk JKM, Osterhaus ADME, Schuitemaker H, and Miedema F: Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 nfection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995;181:1365-1372.
4. Pontesilli O, Klein MR, Kerkhof-Garde SR, Pakker NG, de Wolf F, Schuitemaker H, and Miedema F: Longitudinal analysis of human immunodeficiency virus type-1-specific cytotoxic T lymphocyte response: A predominant Gag-specific response is associated with non-progressive infection. J Infect Dis 1998;178:1008-1018.
5. Harrer T, Harrer E, Kalams SA, Barbosa P, Trocha A, Johnson RP, Elbeik T, Feinberg MB, Buchbinder SP, and Walker BD: Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. J Immunol 1996;156:2616-2623.
6. Cao Y, Qin L, Zhang L, Safrit JJ, and Ho DD: Virologic and immunologic characterizations of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332: 201-208.
7. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, Montefiori D, Orenstein JM, Fox C, Schrager LK, Margolick JB, Buchbinder S, Giorgi JV, and Fauci AS: Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995;332:209-216.
8. + T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 1998;12:1591-1600.
9. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, Goedert JJ, Winkler C, O'Brien SJ, Rinaldo C, Detels R, Blattner W, Phair J, Erlich H, and Mann DL: Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Med 1996;2:405-411.
10. Nelson GW, Kaslow R, and Mann DL: Frequency of HLA allelespecific peptide motifs in HIV-1 proteins correlates with the allele's association with relative rates of disease progression after HIV-1 infection. Proc Natl Acad Sci USA 1997;94:9802-9807.
11. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, and O'Brien SJ: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structure gene. Science 1996;273:1856-1862.
12. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, and Desrosiers RC: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995;332:228-232.
13. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellett A, Chatfield C, Lawson VA, Crowe S, Maerz A, Sonza S, Learmont J, Sullivan JS, Cunningham A, Dwyer D, Dowton D, and J Mills: Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995;270:988-991.
14. De Roda Husman AM, Koot M, Cornelissen M, Keet IPM, Brouwer M, Broersen SM, Bakker M, Roos MTL, Prins M, de Wolf F, Coutinho RA, Miedema F, Goudsmit J, and Schuitemaker H: Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997;127:882-890.
15. Huang Y, Zhang L, and Ho DD: Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection. J Virol 1995;69:93-100.
16. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, O'Brien TR, Jacobson LP, Kaslow R, Buchbinder S, Vittinghoff E, Vlahov D, Hoots K, Hilgartner MW, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study, and O'Brien SJ: Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997; 277:959-965.
17. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, Dean M, Honjo T, Tashiro K, Yabe D, Buchbinder S, Vittinghoff E, Goedert JJ, O'Brien TR, Jacobson LP, Detels R, Donfield S, Willoughby A, Gomperts E, Vlahov D, Phair J, ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), and O'Brien SJ: Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 1998;279:389-393.
18. Ashton LJ, Carr A, Cunningham PH, Roggensack M, McLean K, Law M, Robertson M, Cooper DA, and Kaldor JM: Predictors of progression in long-term nonprogressors. AIDS Res Hum Retroviruses 1998;14:117-121.
19. Van Griensven GJP, Tielman RAP, Goudsmit J, Van der Noordaa J, de Wolf F, de Vroome EMM, and Coutinho RA: Risk factors and prevalence of HIV antibodies in homosexual men in The Netherlands. Am J Epidemiol 1987;125:1048-1057.
20. + T cell count. J Infect Dis 1994;169:1236-1243.
21. Centers for Disease Control: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1993;4(No. RR-17):1-19.
22. Jurriaans S, Van Gemen B, Wevering GJ, Van Strijp D, Nara P, Coutinho RA, Koot M, Schuitemaker H, and Goudsmit J: The natural history of HIV-1 infection: Virus load and virus phenotype independent determinants of clinical course? Virology 1994;204: 223-233.
23. Schellekens PTA, Roos MTL, de Wolf F, Lange JMA, and Miedema F: Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for AIDS in HIV-1 infected men. J Clin Immunol 1990;10:121-127.
24. Pontesilli O, Carlesimo M, Varani AR, Ferrara R, Guerra EC, Bernardi ML, Ricci G, Mazzone AM, D'Offizi G, and Aiuti F: HIV-1 specific lymphoproliferative responses in asymptomatic HIV-infected individuals. Clin Exp Immunol 1995;100:419-424.
25. Klein MR, Veenstra J, Holwerda AM, Roos MTL, Gow I, Patou G, Coutinho RA, de Wolf F, and Miedema F: Gag-specific immune responses after immunization with p17/p24: Ty virus-like particles in HIV type 1-seropositive individuals. AIDS Res Hum Retroviruses 1997;13:393-399.
26. Kelleher AD, Roggensack M, Jaramillo AB, Smith DE, Walker A, Gow I, McMurchie M, Harris J, Patou G, Cooper DA, and the Community HIV Research Network Investigators: Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. AIDS 1998;12:175-182.
27. Pontesilli O, Guerra EC, Ammassari A, Tomino C, Carlesimo M, Antinori A, Tamburrini E, Prozzo A, Seeber AC, Vella S, Ortona L, Aiuti F, and the VaxSyn Protocol Team: Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. AIDS 1998;12:473-480.
28. Rautmann G, Kieny MP, Brandely R, Dott K, Girard M, Montagnier L, and Lecocq JP: HIV-1 core proteins expressed from recombinant vaccinia viruses. AIDS Res Hum Retroviruses 1989; 5:147-157.
29. Lamhamedi-Cherradi S, Culmann-Penciolelli B, Guy B, Duong Ly T, Goujard C, Guillet J-G, and Gomard E: Different patterns of HIV-1 specific cytotoxic T-lymphocyte activity after primary infection. AIDS 1995;9:421-426.
30. Van Baalen CA, Klein MR, Geretti AM, Keet IPM, Miedema F, van Els CACM, and Osterhaus ADME: Selective in vitro expansion of HLA class I-restricted HIV-1 Gag-specific CD8+ T cells: Cytotoxic T-lymphocyte epitopes and precursors frequencies. AIDS 1993;7:781-786.
31. Strijbosch LWG, Buurman WA, Does RJMM, Zinken PH, and Groenewegen G: Limiting dilution assays: Experimental design and statistical analysis. J Immunol Methods 1987;97:133-140.
32. Cornelissen M, Hogervorst E, Zorgdrager F, Hartman S, and Goudsmit J: Maintenance of syncytium inducing phenotype of HIV type 1 is associated with positively charged residues in the HIV type 1 gp 120 V2 domain without fixed positions, elongation or relocated N-linked glycosylation sites. AIDS Res Hum Retroviruses 1995;11:1169-1175.
33. Carotenuto P, Keldermans L, Bakkus M, van Wijk A, Hogervorst E, de Wolf F, and Goudsmit J: Antibody-mediated inhibition of HIV-1 primary isolate replication and plasma viral load in long-term survivors. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15(Suppl. 1):S59-S63.
34. Krowka JF, Stites DP, Jain S, Steimer KS, George-Nascimento C, Gyenes A, Barr PJ, Hollander H, Moss AR, and Homsy JM: Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro. J Clin Invest 1989;83:1198-1203.
35. + cell decline. AIDS Res Hum Retroviruses 1994;10:113-114.
36. Dyer WB, Geczy AF, Kent SJ, McIntyre LB, Blasdall SA, Learmont JC, and Sullivan JS: Lymphoproliferative immune function in the Sydney Blood Bank cohort, infected with natural nefllong terminal repeat mutants, and in other long-term survivors of transfusion-acquired HIV-1 infection. AIDS 1997;11:1565-1574.
37. Mellors JW, Kingsley LA, Rinaldo CR, Todd JA, Hoo BS, Kokka RP, and Gupta P: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-579.
38. Meyer L, Magierowska M, Hubert J-B, Rouzioux C, Deveau C, Sanson F, Debrè P, Delfraissy J-F, Theodorou I, and the SEROCO Study Group: Early protective effect of CCR-5 Δ32 heterozygosity on HIV-1 disease progression: Relationship with viral load. AIDS 1997;11:F73-F78.
39. + T cell responses associated with control of viremia. Science 1997; 278:1447-1450.
40. + cytotoxic T-cell responses during chronic viral infection. J Virol 1994;68:8056-8063.
41. + T-helper cell and a T-killer cell. Nature (London) 1998;393:474-478.
42. Pope M, Betjes MGH, Romani N, Hirmand H, Cameron PU, Hoffman L, Gezelter S, Schuler G, and Steinman RM: Conjugates of dendritic cells and memory T lymphocytes from skin faclitate productive infection with HIV-1. Cell 1994;78:389-398.
43. Eron JJ, Ashby MA, Giordano MF, Chernow M, Reiter WM, Deeks SG, Lavelle JP, Conant MA, Yangco BG, Pate PG, Torres RA, Mitsuyasu RT, and Twaddel T: Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 1996; 348:1547-1551.
44. Dittmer U, Luke W, Stahl-Hennig C, Coulibaly C, Petty H, Bodemer W, Hunsmann G, and Voss G: Early helper T-cell dysfunction in simian immunodeficiency virus but not in human immunodeficiency virus type-2-infected macaques. J Med Primatol 1994;23:298-303.
45. Kent SJ, Corey L, Agy MB, Morton WR, McElrath MJ, and Greenberg PD: Cytotoxic and proliferative T cell responses in HIV-1 infected Macaca nemestrina. J Clin Invest 1995;95:248-256.